Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioma 7Glioblastoma 6Astrocytoma 5Recurrence 3Brain Neoplasms 3Oligodendroglioma 1Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × IL13-PE38 × Clear all
NCT00024570 2014-11-14

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Completed
60 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Recurrence

NCT00378235 2014-11-13

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Withdrawn
CNS

Glioma, Recurrence

NCT00024557 2011-06-06

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

INSYS Therapeutics Inc

Phase 1 Completed
40 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡